Effects of GDF-15 Level in Patients with Membranous Nephropath


ADİKOZALOVA A., AKGUL S. U., DEMİR E., ÇİFTÇİ H. Ş., OĞUZ F. S., YAZICI H., ...Daha Fazla

EXPERIMED, cilt.14, sa.1, ss.40-44, 2024 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.26650/experimed.1403563
  • Dergi Adı: EXPERIMED
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.40-44
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Nephrotic syndrome is the most frequent cause of membranous nephropathy (MN) in adults. Growth differentiation factor (GDF)-15 is a cytokine released under stress and associated with increased incidence of chronic kidney disease and/or decreased renal function in conditions such as diabetic nephropathy, IgA nephropathy, lupus nephritis, and primary MN. The diagnosis of MN is made by biopsy, which is an invasive procedure. A non-invasive biomarker is needed for timely and risk-free diagnosis. This study aimed to estimate the GDF-15 level in patients with MN to determine if it can be used as a noninvasive biomarker for the diagnosis of MN. Materials and Methods: The study included 88 patients with MN. Sera were obtained from peripheral blood collected from the patients. GDF-15 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Results: GDF-15 level was high in older patients that in younger patients. The glomerular filtration rate was low in patients with increased GDF-15 levels. Furthermore, a decrease in GDF-15 levels was observed in patients in remission. Conclusion: GDF-15 level may be used as a biomarker to predict the progression of MN rather than a diagnostic biomarker.